Optex Systems (OPXS) to Report Q4 Fiscal 2025 Financials on December 17
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Newsfilter
- Earnings Report Announcement: Optex Systems has announced that it will report its financial performance for Q4 of fiscal 2025 on December 17, 2025, which is expected to provide key financial data and non-GAAP metrics to help investors assess the company's performance.
- Investor Conference Call: The company will hold an investor conference call on the same day at 5:00 PM ET, where investors can dial (855) 459-0168 or (973) 413-6114 with Conference Code 367887, aimed at enhancing communication with investors.
- Product Background: Founded in 1987, Optex focuses on manufacturing precision optical sighting systems for the U.S. Department of Defense, with products widely used in various military vehicles, demonstrating the company's solid position in the defense market.
- Market Risk Disclosure: The company states that forward-looking statements will be included, highlighting various risk factors such as defense program funding, market competition, and technological changes, reminding investors to consider potential uncertainties.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like OPXS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on OPXS
About OPXS
Optex Systems Holdings, Inc. is a manufacturer of optical sighting systems and assemblies for the United States Department of Defense, foreign military applications, commercial markets, and consumer markets. Its products are installed on various types of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and armored security vehicles and the Stryker family of vehicles, as well as light armored and armored security vehicles. Its segments are Optex Systems and Applied Optics Center. It also manufactures and delivers various periscope configurations, rifle and surveillance sights and night vision optical assemblies. Its product line includes sighting systems, howitzers, other applied optics centers. It delivers its products both directly to the federal government and to prime contractors. In addition, it offers military specification anti-reflective coatings for infrared applications in both the military and commercial markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strategies for Discovering Undervalued Growth Stocks
- Growth Ranking Tool: Benzinga's Growth Ranking tool helps investors identify underappreciated growth stocks by establishing a rules-based framework that reduces narrative risk and focuses on actual sales and earnings growth.
- Screening Process Optimization: With Benzinga Pro's scanner, investors can create a weekly updated list of candidates, initially filtering for high Growth Rankings and then using low institutional ownership to eliminate crowded trades.
- Potential Investment Opportunities: Companies like Optex Systems Holdings and MIND Technology demonstrate real growth potential under low institutional ownership, where stable orders and continued deliveries could lead to rapid market re-pricing.
- Profitability Enhancement: Cases like Paysign and Codere Online indicate that as profitability improves and cash flow stabilizes, market attention on these companies may rise quickly, driving stock prices higher.
Continue Reading
Three Microcap Companies Show Healthy Growth: OPXS, DCTH, MAMA
- OPXS Business Growth: Optex Systems Holdings is experiencing rising revenue and expanding margins through the design and manufacture of advanced optical sighting systems, indicating stable demand and financial health in the defense market.
- DCTH Business Transformation: Delcath Systems is commercializing its FDA-approved liver cancer treatment, with revenue gradually increasing, marking a successful transition from development to execution and addressing a serious medical need.
- MAMA Expansion Momentum: Mama's Creations is growing revenue at a healthy pace through fresh food sales in supermarkets and club stores nationwide, while maintaining operational leverage and balance sheet discipline, showcasing sustainable growth potential.
- Common Traits: All three companies are improving financial quality alongside revenue growth, indicating their long-term investment value in the microcap market, quietly strengthening while the market is distracted.
Continue Reading